3-甲氧基-6-甲基哒嗪 | 17644-83-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-甲氧基-6-甲基哒嗪
• 英文名称: 3-methoxy-6-methylpyridazine
• 英文别名: 6-methyl-3-methoxypyridazine；3-methoxy-6-methyl-pyridazine；3-Methoxy-6-methyl-pyridazin；3-Methyl-6-methoxy-pyridazin；6-Methoxy-3-methyl-pyridazin；3-Methoxy-6-methylpyridazin
• CAS: 17644-83-6
• 化学式: C₆H₈N₂O
• mdl: MFCD09751662
• 分子量: 124.142
• InChiKey: HYTYPAQYQLIQSY-UHFFFAOYSA-N

物化性质

• 熔点：
  135.5 °C
• 沸点：
  210 °C
• 密度：
  1.068±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-甲氧基-6-甲基哒嗪 在 potassium carbonate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 20.33h， 生成 6-methyl-3-methoxypyridazine 1-ethoxycarbonylimide
  参考文献：
  名称：

  Photolysis of pyridazin-3-one 1-imides: Ring contraction into 3-pyrrolin-2-one derivatives.

  摘要：

  对吡嗪-3-酮 1-乙氧基碳酰亚胺（9a）的辐射处理导致环收缩，生成了氮杂马来酰亚胺（11），而6-甲基衍生物（9b）在辐射后则获得了3-吡咯烯-2-酮（12）。另一方面，2-甲基吡嗪-3-酮 1-亚胺（10a, b）的光解反应生成了氮杂马来酰亚胺（13a, b）和3-吡咯烯-2-酮（14a, b）。讨论了这种光诱导环收缩反应的机制。

  DOI：

  10.1248/cpb.33.3540
• 作为产物：
  描述：

  3-氯-6-甲基哒嗪 、 sodium methylate 以 甲醇 为溶剂， 反应 2.0h， 以66.8%的产率得到3-甲氧基-6-甲基哒嗪
  参考文献：
  名称：

  The Synthesis of Pyrrolo[1,2-a]pyrazin-1(2H)-ones and Pyrrolo[1,2-b]pyridazin-6(5H)-ones

  摘要：

  The pyrrolo[1,2-a]pyrazin-1(2H)-ones (10), (11), (12) and (13) and the pyrrolo[1,2-b[pyridazin-6(5H)-one (18) were prepared either a) directly by Chichibabin quaternisation-cyclisation of the corresponding methoxy-methylpyrazine or pyridazine or b) by hydrogen halide hydrolysis of methoxypyrrolo[1,2-a]pyrazines and methoxypyrrolo[1,2-b]pyridazines. Protonation studies and some reactivity of the systems are discussed.

  DOI：

  10.3987/com-92-6085

文献信息

• REAGENT FOR ORGANIC SYNTHESIS REACTION CONTAINING ORGANIC TRIOL BORATE SALT
  申请人：Miyaura Norio

  公开号：US20100087646A1

  公开（公告）日：2010-04-08

  [Problem] To provide an organoboron compound-containing reagent for organic synthesis reactions which undergoes no trimerization with dehydration, does not necessitate activation with a base, and is stable and highly active. [Means for Solving Problems] The reagent for organic synthesis reactions contains an organic triol borate salt represented by any of the general formulae (I) to (III) and general formula (XVI): (wherein R 1 represents alkyl, alkenyl, etc.; R 2 represents optionally substituted alkyl, alkenyl, alkynyl, etc. or represents hydrogen; m + represents an alkaline metal ion, phosphonium ion, or given ammonium ion; M 2+ represents an alkaline earth metal; X represents halogen or alkoxide; Y represents an alkali metal ion, etc.; A represents optionally substituted methylene; and n represents an integer).

  [问题] 提供一种含有有机硼化合物的试剂，用于有机合成反应，该试剂不会发生脱水三聚体化，无需碱激活，稳定且活性高。 [解决问题的方法] 用于有机合成反应的试剂包含由通式(I)至(III)和通式(XVI)中的任一表示的有机三醇硼酸盐，其中R1代表烷基、烯基等；R2代表可选择取代的烷基、烯基、炔基等，或代表氢；m+代表碱金属离子、磷酰离子或给定的铵离子；M2+代表碱土金属；X代表卤素或烷氧基；Y代表碱金属离子等；A代表可选择取代的亚甲基；n代表整数。
• [EN] OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE<br/>[FR] OCTAHYDROCYCLOPENTAPYRROLES, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：UNIV COLUMBIA

  公开号：WO2014152018A1

  公开（公告）日：2014-09-25

  The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatement of diseases characterized by excessive lipofuscin accumulation in the retina.

  本发明提供了具有以下结构的八氢环戊吡咯化合物：(结构表示) 其中psi为不存在或存在，当存在时为键；R1、R2、R3、R4和R5各自独立为H、卤素、CF或C1-C4烷基；R6不存在或存在，当存在时为H、OH或卤素；A不存在或存在，当存在时为C(O)或C(O)NH；B为取代或未取代的单环、双环、杂单环、杂双环、苄基、CO2H或(C1-C4烷基)-CO2H，其中当B为CO2H时，A存在且为C(O)；且当psi存在时，R6不存在，当psi不存在时，R6存在，或其药用可接受盐，用于治疗以视网膜过度脂褐素积聚为特征的疾病。
• 2-(CYCLIC AMINOCARBONYL)INDOLINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1840126A1

  公开（公告）日：2007-10-03

  A compound of the following formula (I): wherein A is a group of the following formula (I-A): wherein X is an oxygen atom or a sulfur atom, R4 is a hydrogen atom, a C1-6 alkyl group, or other, R5 is a hydrogen atom or other; or a heteroaryl group or other optionally substituted with a halogen, a C1-6 alkyl, a C1-6 alkoxy, or other; R1 and R2 are the same or different and are a hydrogen atom, a C1-6 alkyl group or other; R3 is a hydrogen atom, a halogen atom, a C1-6 alkoxy group, or other; Ra and Rb are the same or different and are a hydrogen atom or a C1-6 alkyl group; and n is an integer of 0-5; or a pharmaceutically acceptable acid addition salt thereof, which can selectively act on mitochondrial benzodiazepine receptor and is useful as a medicament for treating/preventing anxiety disorder, depression, epilepsy, dementia, and so on.

  以下是公式（I）的化合物： 其中A是以下公式（I-A）的一个基团： 其中X是氧原子或硫原子，R4是氢原子，C1-6烷基或其他，R5是氢原子或其他；或者是杂环基团或其他，可选择地取代有卤素、C1-6烷基、C1-6烷氧基或其他；R1和R2相同或不同，是氢原子、C1-6烷基或其他；R3是氢原子、卤素原子、C1-6烷氧基或其他；Ra和Rb相同或不同，是氢原子或C1-6烷基；n是0-5的整数；或其药学上可接受的酸盐，可选择性地作用于线粒体苯二氮卓受体，用作治疗/预防焦虑症、抑郁症、癫痫、痴呆等疾病的药物。
• POTASSIUM CHANNEL MODULATORS
  申请人：Cadent Therapeutics, Inc.

  公开号：US20170355708A1

  公开（公告）日：2017-12-14

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.

  提供的是公式(I)的新颖化合物： 以及它们的药用可接受盐，这些化合物用于治疗与钾通道相关的一系列疾病、障碍或状况。还提供了包含公式(I)的新颖化合物的药物组合物，它们的药用可接受盐，以及使用它们来治疗与钾通道相关的一种或多种疾病、障碍或状况的方法。
• 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE
  申请人：Horiuchi Yoshihiro

  公开号：US20120225876A1

  公开（公告）日：2012-09-06

  Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof (In the formula, A represents a group that is represented by formula (A-1); R 1a and R 1b may be the same or different and each independently represents a C 1-6 alkyl group which may be substituted by one to three halogen atoms; m and n each independently represents an integer of 0-5; X 1 represents a hydroxyl group or an aminocarbonyl group; Z 1 represents a single bond or the like; and R 2 represents an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group or the like.)

  公开了一种由公式(1)表示的化合物或其药理可接受的盐(在公式中，A代表由公式(A-1)表示的基团；R1a和R1b可以相同或不同，每个独立地表示一个可以由一个到三个卤素原子取代的C1-6烷基；m和n各自独立地表示0-5之间的整数；X1代表羟基或氨基甲酰基；Z1代表单键等；R2代表一个可选地取代的C1-6烷基，一个可选地取代的C6-10芳基等)。

表征谱图